Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'L-DOPA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 1399 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Sanchez-Pernaute, R; Harvey-White, J; Cunningham, J; Bankiewicz, KS
      Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats

      MOLECULAR THERAPY
    2. Jameson, GNL; Linert, W
      The oxidation of 6-hydroxydopamine in aqueous solution. Part 2. Speciationand product distribution with iron(III) as oxidant

      JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2
    3. Hashimoto, T; Shindo, M; Yanagisawa, N
      Enhanced associated movements in the contralateral limbs elicited by briskvoluntary contraction in choreic disorders

      CLINICAL NEUROPHYSIOLOGY
    4. Hartleb, J; Arndt, R
      Cysteine and indole derivatives as markers for malignant melanoma

      JOURNAL OF CHROMATOGRAPHY B
    5. Jung, YJ; Youn, JY; Ryu, JC; Surh, YJ
      Salsolinol, a naturally occurring tetrahydroisoquinoline alkaloid, inducesDNA damage and chromosomal aberrations in cultured Chinese hamster lung fibroblast cells

      MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
    6. Glasauer, FE
      Restless legs syndrome

      SPINAL CORD
    7. Nutt, JG
      Motor fluctuations and dyskinesia in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    8. Fredriksson, A; Schroder, N; Eriksson, P; Izquierdo, I; Archer, T
      Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits

      PARKINSONISM & RELATED DISORDERS
    9. Rembischevski, P; Gemal, AL
      Determination of the influence of borate ion on the degradation of L-alpha-methyldopa using RP-HPLC with photodiode array detection

      JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    10. Cools, R; Barker, RA; Sahakian, BJ; Robbins, TW
      Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands

      CEREBRAL CORTEX
    11. Furlanut, M; Furlanut, M; Benetello, P
      Monitoring of L-dopa concentrations in Parkinson's disease

      PHARMACOLOGICAL RESEARCH
    12. Tamilarasu, N; Zhang, J; Hwang, S; Rana, TM
      A new strategy for site-specific protein modification: Analysis of a Tat peptide - TAR RNA interaction

      BIOCONJUGATE CHEMISTRY
    13. Zhang, FP; Bi, SP; Li, HZ; Chen, YJ; Dai, LM
      Application of L-dopa as an electroactive ligand for indirect determination of aluminum in biological samples by differential pulse voltammetry

      ELECTROANALYSIS
    14. Brown, DA
      Skin pigmentation enhancers

      JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
    15. Thobois, S; Guillouet, S; Broussolle, E
      Contributions of PET and SPECT to the understanding of the pathophysiologyof Parkinson's disease

      NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY
    16. Bezard, E; Ravenscroft, P; Gross, CE; Crossman, AR; Brotchie, JM
      Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys

      NEUROBIOLOGY OF DISEASE
    17. Schwarz, EJ; Reger, RL; Alexander, GM; Class, R; Azizi, SA; Prockop, DJ
      Rat marrow stromal cells rapidly transduced with a self-inactivating retrovirus synthesize L-DOPA in vitro

      GENE THERAPY
    18. Burzio, LA; Waite, JH
      Reactivity of peptidyl-tyrosine to hydroxylation and cross-linking

      PROTEIN SCIENCE
    19. Yamato, H; Kannari, K; Shen, H; Suda, T; Matsunaga, M
      Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum?

      NEUROREPORT
    20. Ferger, B; Rose, S; Jenner, A; Halliwell, B; Jenner, P
      6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum

      NEUROREPORT
    21. Love, S
      Damage to nuclear DNA in Lewy body disease

      NEUROREPORT
    22. Iravani, MM; Costa, S; Jackson, MJ; Tel, BC; Cannizzaro, C; Pearce, RKB; Jenner, P
      GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed commonmarmosets

      EUROPEAN JOURNAL OF NEUROSCIENCE
    23. Grant, S; Patel, NN; Philp, AR; Grey, CNB; Lucas, RD; Foster, RG; Bowmaker, JK; Jeffery, G
      Rod photopigment deficits in albinos are specific to mammals and arise during retinal development

      VISUAL NEUROSCIENCE
    24. Shen, B; Samaraweera, P; Rosenberg, B; Orlow, SJ
      Ocular albinism type 1: More than meets the eye

      PIGMENT CELL RESEARCH
    25. Pattison, DI; Davies, MJ; Levina, A; Dixon, NE; Lay, PA
      Chromium(VI) reduction by catechol(amine)s results in DNA cleavage in vitro: Relevance to chromium genotoxicity

      CHEMICAL RESEARCH IN TOXICOLOGY
    26. Jung, YJ; Surh, YJ
      Oxidative DNA damage and cytotoxicity induced by copper-stimulated redox cycling of salsolinol, a neurotoxic tetrahydroisoquinoline alkaloid

      FREE RADICAL BIOLOGY AND MEDICINE
    27. Marin, C; Jimenez, A; Bonastre, M; Vila, M; Agid, Y; Hirsch, EC; Tolosa, E
      LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in parkinsonian rats

      SYNAPSE
    28. Cumming, P; Munk, OL; Doudet, D
      Loss of metabolites from monkey striatum during PET with FDOPA

      SYNAPSE
    29. Ruottinen, HM; Niinivirta, M; Bergman, J; Oikonen, V; Solin, O; Eskola, O; Eronen, E; Sonninen, P; Rinne, UK
      Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging

      SYNAPSE
    30. Pinna, A; Fenu, S; Morelli, M
      Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats

      SYNAPSE
    31. Saletu, M; Anderer, P; Saletu, B; Hauer, C; Mandl, M; Semler, B; Saletu-Zyhlarz, G
      Sleep laboratory studies in periodic limb movement disorder (PLMD) patients as compared with normals and acute effects of ropinirole

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    32. Walters, AS; Winkelmann, J; Trenkwalder, C; Fry, JM; Kataria, V; Wagner, M; Sharma, R; Hening, W; Li, L
      Long-term follow-up on restless legs syndrome patients treated with opioids

      MOVEMENT DISORDERS
    33. Yee, RE; Irwin, I; Milonas, C; Stout, DB; Huang, SC; Shoghi-Jadid, K; Satyamurthy, N; Delanney, LE; Togaski, DM; Farahani, KF; Delfani, K; Janson, AM; Phelps, ME; Langston, JW; Barrio, JR
      Novel observations with FDOPA-PET imaging after early nigrostriatal damage

      MOVEMENT DISORDERS
    34. Maratos, EC; Jackson, MJ; Pearce, RKB; Jenner, P
      Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)

      MOVEMENT DISORDERS
    35. Rascol, O; Arnulf, I; Paul, HPS; Brefel-Courbon, C; Vidailhet, M; Thalamas, C; Bonnet, AM; Descombes, S; Bejjani, B; Fabre, N; Montastruc, JL; Agid, Y
      Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

      MOVEMENT DISORDERS
    36. Datla, KP; Blunt, SB; Dexter, DT
      Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, inrats with partial 6-OHDA or FeCl3 nigrostriatal lesions

      MOVEMENT DISORDERS
    37. Petzinger, GM; Quik, M; Ivashina, E; Jakowec, MW; Jakubiak, M; Di Monte, D; Langston, JW
      Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate

      MOVEMENT DISORDERS
    38. Sedlakova, A; Kohut, A; Sarissky, M
      Changes of gastric lipase activity after ethanol and indomethacin administration: Influence of pretreatment with allopurinol, pentoxifylline and L-DOPA

      PHYSIOLOGICAL RESEARCH
    39. Ghaemi, M; Rudolf, J; Hilker, R; Herholz, K; Heiss, WD
      Increased pineal Fdopa uptake is related to severity of Parkinson's disease - A PET study

      JOURNAL OF PINEAL RESEARCH
    40. Silber, MH
      Sleep disorders

      NEUROLOGIC CLINICS
    41. Marcolino-Junior, LH; Teixeira, MFS; Pereira, AV; Fatibello, O
      Flow Injection Determination of levodopa in tablets using a solid-phase reactor containing lead(IV) dioxide immobilized

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    42. Grange, S; Holford, NHG; Guentert, TW
      A pharmacokinetic model to predict the PK interaction of l-dopa and benserazide in rats

      PHARMACEUTICAL RESEARCH
    43. Huang, SY; Hu, JJ; Wang, TT
      Effects of gas composition on the cell growth and L- DOPA production in the suspension culture of Stizolobium hassjoo

      JOURNAL OF THE CHINESE INSTITUTE OF CHEMICAL ENGINEERS
    44. Togasaki, DM; Tan, L; Protell, P; Di Monte, DA; Quik, M; Langston, JW
      Levodopa induces dyskinesias in normal squirrel monkeys

      ANNALS OF NEUROLOGY
    45. Poulikakos, P; Vassilacopoulou, D; Fragoulis, EG
      L-DOPA decarboxylase association with membranes in mouse brain

      NEUROCHEMICAL RESEARCH
    46. Rascol, O; Fabre, N
      Dyskinesia: L-dopa-induced and tardive dyskinesia

      CLINICAL NEUROPHARMACOLOGY
    47. Camicioli, R; Lea, E; Nutt, JG; Sexton, G; Oken, BS
      Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: A pilot study

      CLINICAL NEUROPHARMACOLOGY
    48. Heikkinen, H; Nutt, JG; LeWitt, PA; Koller, WC; Gordin, A
      The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    49. Micallef-Roll, J; Rihet, P; Hasbroucq, T; Possamai, C; Blin, O
      Levodopa-induced drowsiness in healthy volunteers: Results of a choice reaction time test combined with a subjective evaluation of sedation

      CLINICAL NEUROPHARMACOLOGY
    50. Djaldetti, R; Rosmarin, V; Ziv, I; Melamed, E
      The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    51. Offen, D; Panet, H; Galili-Mosberg, R; Melamed, E
      Catechol-O-methyltransferase decreases levodopa toxicity in vitro

      CLINICAL NEUROPHARMACOLOGY
    52. Augustyniak, W; Kanski, R; Kanska, M
      Synthesis of carbon-14 labeled [1-C-14]-, and [2-C-14]-L-tyrosine

      JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
    53. Dudesek, A; Roschinger, W; Muntau, AC; Seidel, J; Leupold, D; Thony, B; Blau, N
      Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency

      EUROPEAN JOURNAL OF PEDIATRICS
    54. Djaldetti, R; Melamed, E
      New therapies for Parkinson's disease

      JOURNAL OF NEUROLOGY
    55. Siddhuraju, P; Becker, K
      Rapid reversed-phase high performance liquid chromatographic method for the quantification of L-Dopa (L-3,4-dihydroxyphenylalanine), non-methylated and methylated tetrahydroisoquinoline compounds from Mucuna beans

      FOOD CHEMISTRY
    56. Sugaya, Y; Sasaki, Y; Goshima, Y; Kitahama, K; Kusakabe, T; Miyamae, T; Kato, T; Misu, Y
      Autoradiographic studies using L-[C-14]DOPA and L-[H-3]DOPA reveal regional NA(+)-dependent uptake of the neurotransmitter candidate L-DOPA in the CNS

      NEUROSCIENCE
    57. Lopez, A; Munoz, A; Guerra, MJ; Labandeira-Garcia, JL
      Mechanisms of the effects of exogenous levodopa on the dopamine-denervatedstriatum

      NEUROSCIENCE
    58. Hadi, N; Singh, S; Ahmad, A; Zaidi, R
      Strand scission in DNA induced by 5-hydroxytryptamine (Serotonin) in the presence of copper ions

      NEUROSCIENCE LETTERS
    59. Muller, T; Woitalla, D; Hauptmann, B; Fowler, B; Kuhn, W
      Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease

      NEUROSCIENCE LETTERS
    60. Itokazu, N; Yamamoto, K; Ouchi, Y; Cyong, JC
      Establishment of L-3,4-dihydroxyphenilalaninde-induced pharmacological dementia model mouse

      NEUROSCIENCE LETTERS
    61. Zucker, M; Weizman, A; Harel, D; Rehavi, M
      Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat substantia nigra and prefrontal cortex induced by psychotropic drugs

      NEUROPSYCHOBIOLOGY
    62. Zeng, BY; Pearce, RKB; MacKenzie, GM; Jenner, P
      Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study

      JOURNAL OF NEURAL TRANSMISSION
    63. Brusa, L; Pierantozzi, M; Peppe, A; Altibrandi, MG; Giacomini, P; Mazzone, P; Stanzione, P
      Deep Brain Stimulation (DBS) attentional effects parallel those of l-dopa treatment

      JOURNAL OF NEURAL TRANSMISSION
    64. Fredriksson, A; Danysz, W; Quack, G; Archer, T
      Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice

      JOURNAL OF NEURAL TRANSMISSION
    65. Gerlach, M; Xiao, AY; Kuhn, W; Lehnfeld, R; Waldmeier, P; Sontag, KH; Riederer, P
      The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats

      JOURNAL OF NEURAL TRANSMISSION
    66. Ferreira, A; Bettencourt, P; Pestana, M; Correia, F; Serrao, P; Martins, L; Cerqueira-Gomes, M; Soares-da-Silva, P
      Heart failure, aging, and renal synthesis of dopamine

      AMERICAN JOURNAL OF KIDNEY DISEASES
    67. Morelli, M; Pinna, A
      Modulation by adenosine A(2A) receptors of dopamine-mediated motor behavior as a basis for antiparkinson's disease drugs

      DRUG DEVELOPMENT RESEARCH
    68. Barzilai, A; Melamed, E; Shirvan, A
      Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    69. Mooslehner, KA; Chan, PM; Xu, WM; Liu, LZ; Smadja, C; Humby, T; Allen, ND; Wilkinson, LS; Emson, PC
      Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism

      MOLECULAR AND CELLULAR BIOLOGY
    70. Villa, P; Soranna, L; Mancini, A; De Marinis, L; Valle, D; Mancuso, S; Lanzone, A
      Effect of feeding on growth hormone response to growth hormone-releasing hormone in polycystic ovarian syndrome: relation with body weight and hyperinsulinism

      HUMAN REPRODUCTION
    71. Soule, SG; Macfarlane, P; Levitt, NS; Millar, RP
      Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men

      SOUTH AFRICAN MEDICAL JOURNAL
    72. Carey, RM
      Renal dopamine system - Paracrine regulator of sodium homeostasis and blood pressure

      HYPERTENSION
    73. Cestelli, A; Catania, C; D'Agostino, S; Di Liegro, I; Licata, L; Schiera, G; Pitarresi, GL; Savettieri, G; De Caro, V; Giandalia, G; Giannola, LI
      Functional feature of a novel model of blood brain barrier: studies on permeation of test compounds

      JOURNAL OF CONTROLLED RELEASE
    74. Diaz, MR; Abdala, P; Barroso-Chinea, P; Obeso, J; Gonzalez-Hernandez, T
      Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease

      BEHAVIOURAL BRAIN RESEARCH
    75. Danielsen, EH; Smith, DF; Andersen, F; Gee, AD; Bender, D; Hansen, SB; Hermansen, F; Ostergaard, L; Cumming, P; Gjedde, A
      FDOPA metabolism in the adult porcine brain: influence of tracer circulation time and VOI selection on estimates of striatal DOPA decarboxylation

      JOURNAL OF NEUROSCIENCE METHODS
    76. Contin, M; Riva, R; Martinelli, P; Albani, F; Avoni, P; Baruzzi, A
      Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach

      THERAPEUTIC DRUG MONITORING
    77. Rein, FN; Rocha, RC; Toma, HE
      Catecholamine complexes of ruthenium-edta and their redox chemistry

      JOURNAL OF INORGANIC BIOCHEMISTRY
    78. Barreto, WJ; Barreto, SRG; Santos, MA; Schimidt, R; Paschoal, FMM; Mangrich, AS; deOliveira, LFC
      Interruption of the MnO2 oxidative process on dopamine and L-dopa by the action of S2O32-

      JOURNAL OF INORGANIC BIOCHEMISTRY
    79. Kunz, D; Bes, F
      Exogenous melatonin in periodic limb movement disorder: An open clinical trial and a hypothesis

      SLEEP
    80. Dimitrakopoulou-Strauss, A; Strauss, LG; Burger, C
      Quantitative PET studies in pretreated melanoma patients: A comparison of 6-[F-18] fluoro-L-dopa with F-18-FDG and O-15-water using compartment and noncompartment analysis

      JOURNAL OF NUCLEAR MEDICINE
    81. Najib, J
      Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease

      CLINICAL THERAPEUTICS
    82. Antonopoulos, VT; Rob, A; Ball, AS; Wilson, MT
      Dechlorination of chlorophenols using extracellular peroxidases produced by Streptomyces albus ATCC 3005

      ENZYME AND MICROBIAL TECHNOLOGY
    83. Hornykiewicz, O
      How L-DOPA was discovered as a drug for Parkinson's disease 40 years ago

      WIENER KLINISCHE WOCHENSCHRIFT
    84. Lees, AJ; Katzenschlager, R; Head, J; Ben-Shlomo, Y
      Ten-year follow-up of three different initial treatments in de-novo PD - Arandomized trial

      NEUROLOGY
    85. Ondo, WG; Vuong, KD; Khan, H; Atassi, F; Kwak, C; Jankovic, J
      Daytime sleepiness and other sleep disorders in Parkinson's disease

      NEUROLOGY
    86. Agid, Y
      Levodopa - Is toxicity a myth?

      NEUROLOGY
    87. Bibbiani, F; Oh, JD; Chase, TN
      Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

      NEUROLOGY
    88. Shoulson, I; Penney, J; McDermott, M; Kieburtz, K; Schwid, SR; Kayson, E; Chase, T; Fahn, S; Greenamyre, JT; Lang, A; Siderowf, A; Pearson, N; Harrison, M; Rost-Ruffner, E; Colcher, A; Lloyd, M; Matthews, M; Pahwa, R; McGuire, D; Lew, MF; Schuman, S; Marek, K; Broshjeit, S; Factor, S; Brown, D; Feigin, A; Mazurkiewicz, J; Ford, B; Jennings, D; Dillon, S; Comella, C; Blasucci, L; Janko, K; Shulman, L; Wiener, W; Bateman-Rodriguez, D; Carrion, A; Suchowersky, O; Lafontaine, AL; Pantella, C; Siemers, E; Belden, J; Davies, R; Lannon, M; Grimes, D; Gray, P; Martin, W; Kennedy, L; Adler, C; Newman, S; Hammerstad, J; Stone, C; Lewitt, P; Bardram, K; Mistura, K; Miyasaki, J; Johnston, L; Cha, JHJ; Tennis, M; Panisset, M; Hall, J; Tetrud, J; Friedlander, J; Hauser, R; Gauger, L; Rodnitzky, R; Deleo, A; Dobson, J; Seeberger, L; Dingmann, C; Tarsy, D; Ryan, P; Elmer, L; Ruzicka, D; Stacy, M; Brewer, M; Locke, B; Baker, D; Casaceli, C; Day, D; Florack, M; Hodgeman, K; Laroia, N; Nobel, R; Orme, C; Rexo, L; Rothenburgh, K; Sulimowicz, K; Watts, A; Wratni, E; Tariot, P; Cox, C; Leventhal, C; Alderfer, V; Craun, AM; Frey, J; McCree, L; McDermott, J; Cooper, J; Holdich, T; Read, B
      A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease

      NEUROLOGY
    89. Olanow, CW; Watts, RL; Koller, WC
      An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines

      NEUROLOGY
    90. Stiasny, K; Wetter, TC; Winkelmann, J; Brandenburg, U; Penzel, T; Rubin, M; Hundemer, HP; Oertel, WH; Trenkwalder, C
      Long-term effects of pergolide in the treatment of restless legs syndrome

      NEUROLOGY
    91. Trenkwalder, C; Wetter, TC; Stiasny, K; Clarenbach, P
      Restless legs syndrome and periodic limb movements in sleep

      NERVENARZT
    92. Winkelmann, J; Trenkwalder, C
      Pathophysiology of restless legs syndrome - the present state of research

      NERVENARZT
    93. Yang, C; Mitra, AK
      Nasal absorption of tyrosine-linked model compounds

      JOURNAL OF PHARMACEUTICAL SCIENCES
    94. Chen, FY; Uang, BJ
      Enantioselective synthesis of (R)-3-(3,4-dihydroxyphenyl)alanine from tert-butyl glycinate

      JOURNAL OF ORGANIC CHEMISTRY
    95. Katayama, Y; Kasai, M; Oshima, H; Fukaya, C; Yamamoto, T; Ogawa, K; Mizutani, T
      Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients

      JOURNAL OF NEUROSURGERY
    96. Nakao, N; Kakishita, K; Uematsu, Y; Yoshimasu, T; Bessho, T; Nakai, K; Naito, Y; Itakura, T
      Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease

      JOURNAL OF NEUROSURGERY
    97. Lievens, JC; Salin, P; Nieoullon, A; Kerkerian-Le Goff, L
      Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA andprotein expression in the rat striatum

      JOURNAL OF NEUROCHEMISTRY
    98. Rodriguez-Martin, E; Canals, S; Casarejos, MJ; de Bernardo, S; Handler, A; Mena, MA
      L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells

      JOURNAL OF NEUROCHEMISTRY
    99. Weingarten, P; Bermak, J; Zhou, QY
      Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidants

      JOURNAL OF NEUROCHEMISTRY
    100. Kannari, K; Yamato, H; Shen, H; Tomiyama, M; Suda, T; Matsunaga, M
      Activation of 5-HT1A but not 5-HT1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation

      JOURNAL OF NEUROCHEMISTRY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/08/20 alle ore 19:49:49